User profiles for "author:F Iannone"
 | Florenzo Iannoneprofessore reumatologia Verified email at uniba.it Cited by 15896 |
The pathophysiology of osteoarthritis
F Iannone, G Lapadula - Aging clinical and experimental research, 2003 - Springer
Osteoarthritis (OA) is a complex disease whose pathogenesis includes the contribution of
biomechanical and metabolic factors which, altering the tissue homeostasis of articular …
biomechanical and metabolic factors which, altering the tissue homeostasis of articular …
Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in …
OBJECTIVE: To evaluate the risk of serious infections (SIs) in RA patients receiving anti-TNF
therapy on the basis of the data included in the GISEA register. METHODS: The study …
therapy on the basis of the data included in the GISEA register. METHODS: The study …
Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice
Since the introduction of biologics for the treatment of rheumatoid arthritis (RA), psoriatic
arthritis (PsA), ankylosing spondylitis (AS), and psoriasis (Pso) an increased risk of …
arthritis (PsA), ankylosing spondylitis (AS), and psoriasis (Pso) an increased risk of …
Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database
…, U Müller-Ladner, O Distler, F Iannone… - Annals of the …, 2010 - ard.bmj.com
Objectives To determine the causes and predictors of mortality in systemic sclerosis (SSc).
Methods Patients with SSc (n= 5860) fulfilling the American College of Rheumatology …
Methods Patients with SSc (n= 5860) fulfilling the American College of Rheumatology …
Mapping and predicting mortality from systemic sclerosis
…, P Caramaschi, O Distler, F Iannone… - Annals of the …, 2017 - ard.bmj.com
Objectives To determine the causes of death and risk factors in systemic sclerosis (SSc).
Methods Between 2000 and 2011, we examined the death certificates of all French patients …
Methods Between 2000 and 2011, we examined the death certificates of all French patients …
Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients' subgroups
…, F Franceschini, R Meliconi, M Casato, F Iannone… - Journal of …, 2021 - Elsevier
Autoimmune systemic diseases (ASD) may show impaired immunogenicity to COVID-19
vaccines. Our prospective observational multicenter study aimed to evaluate the …
vaccines. Our prospective observational multicenter study aimed to evaluate the …
Mepolizumab for eosinophilic granulomatosis with polyangiitis: a European multicenter observational study
…, A Egan, B Seeliger, F Iannone… - Arthritis & …, 2022 - Wiley Online Library
Objective Mepolizumab proved to be an efficacious treatment for eosinophilic
granulomatosis with polyangiitis (EGPA) at a dose of 300 mg every 4 weeks in the …
granulomatosis with polyangiitis (EGPA) at a dose of 300 mg every 4 weeks in the …
[HTML][HTML] Clinical spectrum time course in anti Jo-1 positive antisynthetase syndrome: results from an international retrospective multicenter study
…, S Castaneda, WAS Giraldo, R Caporali, F Iannone… - Medicine, 2015 - journals.lww.com
Anti Jo-1 antibodies are the main markers of the antisynthetase syndrome (ASSD), an
autoimmune disease clinically characterized by the occurrence of arthritis, myositis, and …
autoimmune disease clinically characterized by the occurrence of arthritis, myositis, and …
Increased expression of nerve growth factor (NGF) and high affinity NGF receptor (p140 TrkA) in human osteoarthritic chondrocytes
Objective. We aimed to investigate the expression of nerve growth factor (NGF) and high
affinity NGF receptor (p140 TrkA) on chondrocytes from human healthy and osteoarthritic …
affinity NGF receptor (p140 TrkA) on chondrocytes from human healthy and osteoarthritic …
Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study
…, ME Truchetet, Y Braun-Moscovici, F Iannone… - Annals of the …, 2019 - ard.bmj.com
Objective To assess the safety and efficacy of rituximab in systemic sclerosis (SSc) in clinical
practice. Methods We performed a prospective study including patients with SSc from the …
practice. Methods We performed a prospective study including patients with SSc from the …